

20 December 2022

Sale of Investment in Omni Innovation

EVE Health Group (ASX:EVE, EVE or the Company), a vertically integrated health, nutrition, and wellness company advises that the sale of its approximately 38% interest in Omni Innovation to Myopharm Limited has been completed (see ASX release 16 September 2022).

EVE's portion of the proceeds of the share sale and distribution of net cash proceeds are approximately \$330,000. The funds from the disposal of the investment are in line with the Company's carrying value of the investment in Omni Innovation as disclosed in the Company's Annual Report.

The Company is also continuing to review new business opportunities in order to grow the Company's health and wellness portfolio

Authorised for release by Bill Fry, Managing Director.

— ENDS —

For more information, please contact:

Company enquiries

Bill Fry, Managing Director & CEO
EVE Health Group Ltd
+61 8 6465 5500
billf@evehealthgroup.com.au

About EVE Health Group

EVE Health Group, (ASX: EVE) is a leading, vertically integrated producer of branded nutrition, health and wellness products. The Company has global reach and application to fast-growing markets across Australia and New Zealand, Asia Pacific and North America. Our mission is to create high quality, innovative, natural and sustainable health and wellness products that help the wellbeing of consumers and in turn help our people, shareholders and community prosper.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn or Twitter.



EVE HEALTH GROUP LIMITED



@EVEHEALTHGROUP



WWW.EVEHEALTHGROUP.COM.AU

SUITE 1, 245 CHURCHILL AVENUE
SUBIACO, WA 6008, AUSTRALIA
OFFICE: +61 8 6465 5500